![Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider](https://i2.wp.com/ml-eu.globenewswire.com/media/YzE0NTAzYzMtNzcwMS00NWRjLWJhMTAtM2I1ZjkxM2JkZjI0LTEyMjA5NDYtMjAyNS0wNC0wNC1lbg==/tiny/Zelluna-ASA.png?w=150&resize=150,150&ssl=1 "Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider")
Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson’s Disease Patients
HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE…
George Clinical Welcomes Tony Proctor as Chief Financial Officer
SINGAPORE, Dec. 2, 2024 /PRNewswire/ -- George Clinical, a leading global clinical…
Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer
November 26, 2024 03:00 ET | Source: Anocca AB Application to the…
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
FDA Project Team supports the company’s proposed Phase 3 trial strategy, including…
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
-- SRC recommended that the trial escalate to the next dose level…
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on…
Foundation for Sarcoidosis Research (FSR) receives confirmation from the Department of Labor (DOL) ensuring patient access to FMLA for participation in clinical trials
CHICAGO, Nov. 16, 2024 (GLOBE NEWSWIRE) -- In August of 2023, the…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…
Foundation for Sarcoidosis Research (FSR) receives confirmation from the Department of Labor (DOL) ensuring patient access to FMLA for participation in clinical trials
CHICAGO, Nov. 16, 2024 (GLOBE NEWSWIRE) -- In August of 2023, the…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…